account_balance
Investment manager · 13F filer · SEC CIK 2013410
FCPM III Services B.v.
Reported value$750Mas of Jun 30, 2026
Positions11 1 new, 0 sold out
Top 10 weight99.9%NAMS alone is 38%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
This fund reports 11 stocks.
NAMSNewamsterdam Pharma Company
38.3%Trimmed −8%
MPLTMaplight Therapeutics Inc
15.4%
DYNDyne Therapeutics Inc
11.4%Trimmed −17%
VORVor Biopharma Inc
10.1%
DMRADamora Therapeutics Inc
8.5%
REPLReplimune Group Inc
4.1%
CBIOCrescent Biopharma Inc.
4.0%
AURAAura Biosciences Inc
3.8%New
Engene Holdings Inc2.2%
BCYC2.0%NAMSNewamsterdam Pharma Company
38.3%Trimmed −8%
MPLTMaplight Therapeutics Inc
15.4%
DYNDyne Therapeutics Inc
11.4%Trimmed −17%
VOR10.1%DMRA8.5%REPL4.1%CBIO4.0%AURA3.8%Engene Holdings Inc
BCYCBox size is the share of the fund. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 11 as a list
NAMS Newamsterdam Pharma Company 38.3% Trimmed −8%MPLT Maplight Therapeutics Inc 15.4% HeldDYN Dyne Therapeutics Inc 11.4% Trimmed −17%VOR Vor Biopharma Inc 10.1% HeldDMRA Damora Therapeutics Inc 8.5% HeldREPL Replimune Group Inc 4.1% HeldCBIO Crescent Biopharma Inc. 4.0% HeldAURA Aura Biosciences Inc 3.8% New
Engene Holdings Inc 2.2% Held
BCYC Bicycle Therapeutics PLC 2.0% HeldEngene Holdings Inc 0.1% Held
What changed